Tak-672
Acquired Hemophilia A
TakedaUNKNOWNPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Acquired Hemophilia A cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rituximab Peking Union Medical College Hospital | Phase 4 | BB |
Cyclophosphamide Peking Union Medical College Hospital | Phase 4 | BB |
Daratumumab Institute of Hematology & Blood Diseases Hospital, China | Phase 4 | BB |
Emicizumab University of Washington | Phase 2 | B |
Bortezomib Peking Union Medical College Hospital | Phase 2 | CCC |
Obi-1 Baxalta now part of Shire | Phase 2/3 | CCC |
Susoctocog Alfa Takeda | Unknown | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →